Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 19

recruiting
3 968
countries
28
conditions
2 103

301 trials match your criteria

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan

Infection

Not recruiting

Title: Study of gentamicin, vancomycin and cefazolin antibiotics to prevent infections in women having breast reconstruction surgery with implants

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium

Colon cancer

Not recruiting

Study on the Effects of Capecitabine and Oxaliplatin in Patients with Locally Advanced Colon Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Renal cell carcinoma

Not recruiting

Study of Dabrafenib and Drug Combination for Patients with Metastatic Non-Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib

Neoplasm

Not recruiting

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Df1001

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide

Gastric cancer+7

Not recruiting

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab

Breast neoplasm

Not recruiting

Study Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Endometrial cancer

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.